Navigation Links
Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
Date:12/11/2011

and Efficacy of Continued Treatment -- the BABY HUG Follow-up Study [Abstract 7]

Hydroxyurea is the only federally approved therapy to prevent sickle cell complications in adults with sickle cell anemia (SCA). However, based on positive results from previous trials assessing clinical benefits for use in children, specialists are increasingly considering the use of hydroxyurea in their pediatric patients. Results from the BABY HUG Follow-up Study I suggest that continued use of hydroxyurea is both safe and effective in infants with SCA.

The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) was a multicenter, randomized clinical trial that assessed the clinical benefits of hydroxyurea in very young patients with SCA. Results from the study demonstrated that hydroxyurea administered to infants with SCA provided substantial clinical benefit over placebo.

Researchers launched the BABY HUG Follow-Up Study I in 2008 to assess the safety and efficacy of continued treatment with hydroxyurea in infants with SCA. The Follow-Up Study I included 163 children between the ages of 28 and 44 months who had participated in the BABY HUG trial and who had completed at least 18 months of randomized treatment of either hydroxyurea or placebo. Investigators collected clinical and laboratory data every six months from patient medical records, including use and dosage of hydroxyurea, blood counts, clinical imaging, and frequency of sickle cell-related complications.

At Follow-Up Study entry, families enrolling their children did not know their child's randomized study treatment assignment in BABY HUG; 82 percent initially chose clinical prescription of open-label hydroxyurea, demonstrating a high acceptance rate for the drug. Through the 36 months of follow-up, acceptance remained high, with 68 to 75 percent of the participating families reporting that their children continued
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
2. OpenClinica EDC Solution Deployed for Retina Implant Studies
3. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
4. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
5. NIST studies how new helium ion microscope measures up
6. Five New Clinical Studies Show Value of Masimo PVI & PI
7. ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
8. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
9. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
10. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine” or the “Company”) ... press release disseminated this morning by PR Web, and ... press release states that Immunovaccine has entered into a ... release did not originate from Immunovaccine and there is ... release. Please note that all official statements by ...
(Date:2/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has ... Trypsin" report to their offering. , ... comprehensive data on Trypsin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... 20 L.J. Star , Inc., ... indicators, announced that it has a suite of solutions for the special ... , , ... connect and visually monitor fluid flows, and thereby help maintain strict control ...
... WORCESTER, Mass. An algorithm developed by Ki H. ... at Worcester Polytechnic Institute (WPI), in partnership with Snehraj ... a new heart monitoring system to detect incidents of ... arrhythmia, far more accurately than previous methods. The algorithm, ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at the Citi Investment ... 26, 2010 at 3:00 p.m. ET / 12:00 p.m. ... Pharmaceuticals, will provide a corporate overview. , ... The presentation will be webcast live through the "Investors" section of Amylin,s corporate ...
Cached Biology Technology:L.J. Star Announces Stainless Sanitary Fittings, Sight Glasses and Sight Flow Indicators for the Special Demands of the Pharmaceutical Industry 2L.J. Star Announces Stainless Sanitary Fittings, Sight Glasses and Sight Flow Indicators for the Special Demands of the Pharmaceutical Industry 3L.J. Star Announces Stainless Sanitary Fittings, Sight Glasses and Sight Flow Indicators for the Special Demands of the Pharmaceutical Industry 4Detection of potentially deadly atrial fibrillation dramatically improved by new algorithm 2Detection of potentially deadly atrial fibrillation dramatically improved by new algorithm 3Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference 2
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and ... and Voice Biometrics. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... and Latin America . Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... made great strides in identifying genes that lead to ... result in a continuum of social deficits, communication difficulties ... how exactly these genetic risk factors impact the brain,s ... can be developed. This led researchers ...
... ice in the Arctic melting to record lows in ... to their environment. Yet some crustaceans, previously thought to ... ice, were recently discovered to migrate deep underwater and ... disappears. "Our findings provide a basic new understanding ...
... TUCSON, Ariz. (Sept. 13, 2012) -- Shane Snyder, who ... American Water Works Association (AWWA), has been invited to ... of 3,500 at the 2012 International Water Association,s (IWA) ... engineering professor,s presentation will focus not only on his ...
Cached Biology News:Study reveals how common gene mutation affects kids with autism spectrum disorders 2Study reveals how common gene mutation affects kids with autism spectrum disorders 3Surviving without ice 2UA engineering professor Shane Snyder to speak in Korea on international water quality 2
... Modification of Ham's F-12 was developed for ... viral fusion. The modification consists of doubling ... ascorbic acid. The salt concentrations have been ... mg zinc sulfate per liter, which may ...
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
... The EpiTect Bisulfite Kit enables complete ... in less than 6 hours. The ... protection against DNA degradation and a ... guarantee fast and reliable results for ...
... RNA sequences from high throughput synthesis are new ... LC Sciences. These products provide a large number ... sequences delivered in a microtube as a mixture ... verified RNA sequence. This is a custom product ...
Biology Products: